The US Federal Trade Commission doubled down on its efforts to halt the close of Amgen, Inc.’s proposed acquisition of Horizon Therapeutics plc until a final decision is made on its administrative complaint opposing the deal, asking a district court to issue a preliminary injunction by 31 October.
In a redacted 14 July memorandum supporting a preliminary injunction, the FTC and six states reiterated that post-merger, Amgen...





